KeyPedia buys riskbased.ai to expand FDA device analytics

KeyPedia acquired riskbased.ai on June 30, 2026, adding FDA MAUDE analytics and device surveillance tools to its regulatory intelligence platform. The deal expands KeyPedia’s reach into medical devices, combination products and biologics, while riskbased.ai continues as an independent platform during integration.

Why it matters: - The acquisition gives KeyPedia a deeper foothold in medical device regulatory analytics, especially for high-risk Class III devices where post-market surveillance is critical. - KeyPedia is expanding beyond drug and compliance workflows into devices, combination products and biologics. - The combined platform is aimed at teams that need faster FDA risk detection, reporting support and AI-driven monitoring.

What happened: - KeyPedia, formerly Global Key Solutions Corp., acquired riskbased.ai on June 30, 2026. - The deal adds one of the longest-standing FDA MAUDE analytics platforms to KeyPedia’s regulatory intelligence offering. - No financial terms were disclosed. - The riskbased.ai founding team joined the KeyPedia advisory board.

The details: - riskbased.ai already has signups and active use from major device manufacturers, including a top 5 insulin Class III device company. - The platform’s data coverage includes high-risk Class III devices. - riskbased.ai will continue operating as an independent platform. - Integrations into KeyPedia will roll out across the next few product updates for existing users. - The combined product roadmap includes MedTech Module 510K predicate tree, AI adverse event monitoring, recall prediction, risk management, PSUR, competitive benchmarking and MAUDE-based products. - KeyPedia describes its platform as a data product for life science leaders looking to modernize AI GxP workflows. - KeyPedia says it provides FDA data across training, updates and enforcement signals. - riskbased.ai, operated by Risktech Domains Inc., offers MAUDE adverse-event analytics, RecallALERT, AlphaSPIKE and CorpTRACK. - riskbased.ai says it harmonizes government datasets into audit-ready insights and has been recognized by openFDA and MedTech Leading Voice.

Between the lines: - The deal signals a push to bundle FDA data, AI and device-specific surveillance tools into one workflow. - The focus on biologics and biotech suggests KeyPedia is targeting earlier-stage companies as well as established device manufacturers. - The emphasis on FDA ELSA Enforcement and a risk-based approach points to a bet that regulatory automation will matter more as oversight tightens.

What's next: - KeyPedia said integrations will appear in the next few product updates. - Both platforms will continue developing device and surveillance tools for existing customers. - The combined team will keep building out FDA analytics products for quality and regulatory users. - Zephaniah Odidika said the acquisition broadens analytics for medical devices and combination products and adds biologics and biotech focus to the platform. - Jesse Chen said the combination positions organizations for the future of FDA data and AI/ML enforcement workflows.